Dicyandiamide (DCD), which is otherwise called 2-Cyanoguanidine, is an antacid, hydrophilic white crystalline compound. Dicyandiamide is basically utilized as crude material for dynamic pharmaceutical fixings generation for making hostile to diabetic medications. It is additionally utilized as a relieving specialist in epoxy pitches and covers for circuit sheets and cements. It is additionally utilized underway of natural synthetics, which incorporate, water treatment synthetic substances, slow and controlled nitrogen discharge composts, color fixing specialists, and pharmaceuticals. Dicyandiamide are of various evaluations dependent on immaculateness. The evaluations incorporate pharmaceutical evaluation, electronic evaluation, modern evaluation, and others. At present, pharmaceutical evaluation dicyandiamide is for the most part utilized contrasted with different kinds. The dicyandiamide market is growing at a noteworthy rate. Asia Pacific is foreseen to command the market during the conjecture time frame, trailed by North America and Europe.
- Rise in Demand for Metformin from the Rising Diabetic Population across the Globe
Diabetes is one of the most common and rapidly increasing diseases across the globe. Diabetes is often referred to by doctors as diabetes mellitus. More than 400 million people across the globe are currently suffering from diabetes mellitus. Approximately 552 million people are anticipated to suffer from diabetes by 2030. Type 2 diabetes is the most common type and accounts for more than 90% of all cases of diabetes. Rise in diabetic population across the globe is ascribed to the rise in urbanization, changing population, increasing prevalence of obesity, and lack of physical activity.
The information Presented in this Review is Based on Press-Release by TMR
Dicyandiamide is primarily used in the production of active pharmaceutical ingredients (APIs), which are used in production of metformin, a preferred drug for the treatment of type 2 diabetes mellitus. Metformin is also used in the treatment of excess weight and obesity. Metformin improves glucose tolerance in diabetic patients, lowering basal and postprandial plasma glucose. Asia Pacific is the key metformin producing and exporting region across the globe. Hence, rising demand for dicyandiamide in this region is expected to drive the dicyandiamide market during the next few years.
